| Literature DB >> 30892008 |
Jiantong Dong1, Ryan Y Zhang, Na Sun2, Matthew Smalley, Zipeng Wu, Anqi Zhou, Shih-Jie Chou3, Yu Jen Jan4, Peng Yang, Lirong Bao, Dongping Qi, Xinghong Tang, Patrick Tseng, Yue Hua, Dianwen Xu, Rueihung Kao, Meng Meng5, Xirun Zheng6, Ying Liu6, Tatyana Vagner7, Xiaoshu Chai6, Dongjing Zhou6, Mengyuan Li1, Shih-Hwa Chiou3, Guangjuan Zheng6, Dolores Di Vizio7, Vatche G Agopian, Edwin Posadas4, Steven J Jonas, Shin-Pon Ju8, Paul S Weiss, Meiping Zhao1, Hsian-Rong Tseng, Yazhen Zhu6.
Abstract
Tumor-derived extracellular vesicles (EVs) present in bodily fluids are emerging liquid biopsy markers for non-invasive cancer diagnosis and treatment monitoring. Because the majority of EVs in circulation are not of tumor origin, it is critical to develop new platforms capable of enriching tumor-derived EVs from the blood. Herein, we introduce a biostructure-inspired NanoVilli Chip, capable of highly efficient and reproducible immunoaffinity capture of tumor-derived EVs from blood plasma samples. Anti-EpCAM-grafted silicon nanowire arrays were engineered to mimic the distinctive structures of intestinal microvilli, dramatically increasing surface area and enhancing tumor-derived EV capture. RNA in the captured EVs can be recovered for downstream molecular analyses by reverse transcription Droplet Digital PCR. We demonstrate that this assay can be applied to monitor the dynamic changes of ROS1 rearrangements and epidermal growth factor receptor T790M mutations that predict treatment responses and disease progression in non-small cell lung cancer patients.Entities:
Keywords: EGFR T790M mutation; ROS1 rearrangements; extracellular vesicles; microfluidics; nanosubstrates; non-small cell lung cancer
Mesh：
Substances：
Year: 2019 PMID： 30892008 PMCID： PMC6545291 DOI： 10.1021/acsami.9b01406
Source DB: PubMed Journal: ACS Appl Mater Interfaces ISSN： 1944-8244 Impact factor: 9.229